Lactate Dehydrogenase in Estrogen-responsive Human Breast Cancer Cells

Robert E. Burke, Steven C. Harris, and William L. McGuire

Departments of Medicine [R. E. B., W. L. M.] and Pathology [S. C. H.], The University of Texas Health Science Center, San Antonio, Texas 78284

ABSTRACT

Lactate dehydrogenase activity (LDH) was measured in the MCF-7 human breast cancer cell line derived at the Michigan Cancer Foundation from a patient with metastatic breast adenocarcinoma. LDH was found in the 46,000 x g supernatant of cell lysates, but not in the culture medium. Only the fifth isozyme (LDH-5) could be demonstrated by cellulose acetate electrophoresis and relative heat inactivation studies.

When endogenous steroids were removed from the medium, addition of estrogen to the growth medium for several days elevated LDH 2-fold above controls; LDH was not altered when MCF-7 cells were treated with progesterone, hydrocortisone, prolactin, insulin, or triiodothyronine. A physiological concentration (0.1 nm) of 17β-estradiol was sufficient to produce a maximal LDH increase. There were no qualitative isozyme changes in response to estrogen.

LDH activity may therefore be a useful marker protein for studying hormone action in the MCF-7 human breast cancer cell line.

INTRODUCTION

The MCF-7 cell line (a human breast cancer cell line derived at the Michigan Cancer Foundation from a patient with metastatic breast adenocarcinoma) (18) has been used extensively to study the molecular interactions of estrogens and antiestrogens with the estrogen receptor (1, 8-10); presumably, the action of receptor binding to ligand is followed by gene activation and subsequent estrogen-dependent events. Estrogen has been shown to alter growth (11) and progesterone receptor levels (8) in MCF-7 cells. Thus, the MCF-7 cell line appears to offer an opportunity to study, under very defined conditions, the interrelationships of gene regulation and growth control of human breast cancer cells by estrogen.

LDH³ is well known to be elevated in human neoplastic disease. A recent demonstration that LDH is useful for monitoring human tumor growth in athymic mice suggests a possible role for LDH in analyses of antitumor therapy (15). The potential use of patient tumor patterns of LDH (and other glycolytic enzyme activities) in conjunction with estrogen receptor analysis (13) for selecting breast cancer patients for hormone and/or chemotherapy has also been postulated (17). Goldman et al. (4) first demonstrated that total LDH activity was directly related to the degree of cancer of human breast tumors. Hilf et al. (6) more recently showed a 2-fold greater LDH activity in infiltrating ductal carcinoma than in benign proliferative disease and normal breast tissue. They also showed a significant increase in the proportion of the LDH-5 isozyme in neoplasia. Patient sera patterns of LDH have also been reported to have potential prognostic significance in human breast cancer (16). Many human breast tumors have been found to be estrogen dependent; furthermore, estrogen is capable of elevating LDH-5 in mammalian uteri (5). For these reasons it seemed worthwhile to investigate LDH activity as a potential marker of estrogen action in the hormone-responsive MCF-7 human breast cancer cells.

MATERIALS AND METHODS

Cell Cultures. MCF-7 human breast cancer cell line at passage 102 was originally obtained from Dr. H. D. Soule at the Michigan Cancer Foundation. Except for initial passages with 0.125% trypsin:1 mM EDTA:HBSS to remove cells from culture vessels. Cells were grown at 37° under a 5% CO₂:95% air, high-humidity atmosphere in Eagle's autoclavable MEM, supplemented with 1% nonessential amino acids, 1% glutamine, 5% calf serum, bovine insulin (6 ng/ml), 0.5% saturated sodium bicarbonate, and gentamicin (25 µg/ml). For experiments, 1,000,000 cells were plated into Corning plastic 75 sq cm T-flasks, with culture medium, addition of estrogen to the growth medium for several days elevated LDH 2-fold above controls; LDH was not altered when MCF-7 cells were treated with progesterone, hydrocortisone, prolactin, insulin, or triiodothyronine. A physiological concentration (0.1 nm) of 17β-estradiol was sufficient to produce a maximal LDH increase. There were no qualitative isozyme changes in response to estrogen.

LDH activity may therefore be a useful marker protein for studying hormone action in the MCF-7 human breast cancer cell line.

1 Supported in part by grants from the National Cancer Institute (CA 11378, CB 23862, and CA 9042), the American Cancer Society (BC-23G), and the Medical Research Service of the Audie L. Murphy Veterans Administration Hospital, San Antonio, Texas.
2 To whom requests for reprints should be addressed.
3 The abbreviations used are: LDH, lactate dehydrogenase (L Lactate:NAD⁺ oxidoreductase, EC 1.1.1.27); HBSS, Ca⁺⁺-Mg⁺⁺-free Hanks' balanced salt solution; MEM, minimal essential medium.

Received March 9, 1978; accepted May 30, 1978.
that 100% of the cells were ruptured, as indicated by trypan blue dye uptake.

**DNA and Protein Quantitation.** Frozen cell aliquots were thawed, hydrolyzed in 0.56 M perchloric acid, and then assayed for DNA content according to the diphenylamine method of Burton (2). Protein content of the cell lysates was measured according to the method of Lowry et al. (12), using bovine serum albumin as the standard.

**LDH Assay.** The LDH assay was performed according to the method of Wacker (19), as modified by Calbiochem (Los Angeles, Calif.). The conversion of L-lactate to pyruvate was measured at 28° with the use of Calbiochem reagents and control human sera standards. Initial readings were made 30 sec after addition of the sample to the reaction mixture, and a final reading was taken 2 min later. Experimental samples were diluted with 0.9% NaCl solution to give activities yielding an absorbance change at 340 nm less than 0.200.

**Electrophoresis.** LDH electrophoresis was performed on cellulose acetate with the use of the Dade Iso-Form System (Dade Division, American Hospital Supply Corporation, Miami, Fla.), which is a modification of the staining procedure originally described by Opher (14). Also used were barbital buffer (pH 8.6; ionic strength, 0.075), Beckman Microzone electrophoresis system, and a scanning densitometer (Helena Laboratories Corp., Beaumont, Texas).

**Chemicals.** Calf serum, nonessential amino acids, glutamine, and MEM were purchased from Grand Island Biological Co., Grand Island, N. Y. Bovine insulin, 3,3',5-triiodothyronine, and progesterone were purchased from Sigma Chemical Co., St. Louis, Mo. and 17β-estradiol, hydrocortisone, and LDH assay reagents were purchased from Calbiochem. Prolactin (NIH-P-S-12 ovine) was donated by National Institute of Arthritis, Metabolic, and Digestive Diseases (Bethesda, Md.).

**RESULTS**

We first determined optimal assay conditions and the characteristics of the LDH reaction with the use of either MCF-7 cell lysates or standard human serum (Caltrol II) as depicted in Chart 1. Regardless of the rate, the reaction is linear up to an absorbance change of 0.250. Consequently, all experimental samples were diluted to maintain linear kinetics.

Human serum and MCF-7 cell lysates were heated at 65° for 35 min, a treatment to which LDH-1 is known to be resistant (20). This treatment totally eliminated LDH activity in cell lysates, while some activity was retained in serum that is a mixture of isoenzymes (Table 1). Mixtures of lysate and serum gave the results expected from simple dilution. We find that levels of LDH activity in untreated MCF-7 cell lysates were routinely 100- to 1000-fold greater than in the standard human sera when they are expressed per mg protein. LDH activity was not detectable in the cell culture medium.

Since the heat inactivation suggested that LDH-1 was not present in cell lysates, it became necessary qualitatively to characterize the enzyme activity in the cell lysates. The cellulose acetate electrophoretic pattern shown in Chart 2 illustrates the form of LDH present in MCF-7 cells. Only the LDH-5 isoenzyme appears to be present.

Although it had no effect on the qualitative electrophoretic pattern, estradiol more than doubled LDH activity above untreated cells (Table 1; Chart 3). Estrogen-stimulated LDH activity was apparent only after 3 or 4 days of treatment, regardless of whether cells were in logarithmic or confluent phases of growth. Chart 4 shows that at 5 days of treatment maximal responses were obtained with concentrations of 0.1 nM or greater. Other natural estrogens, estrone and estriol, similarly stimulated LDH activity (data not shown). However, LDH was not altered in cells treated for 10 days with progesterone (0.1 nM to 1.0 μM), hydrocortisone (10 nM), triiodothyronine (0.1 nM or 1.0 μM), prolactin (0.4 nM to 0.04 μM), or insulin (0.01 nM to 0.1 μM).

**DISCUSSION**

LDH is an ubiquitous enzyme that functions in a regulatory manner at a key point in normal intermediary metabo-

Table 1

<table>
<thead>
<tr>
<th>Sample</th>
<th>Control</th>
<th>Heated</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7 cell lysates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Untreated control</td>
<td>602</td>
<td>0</td>
</tr>
<tr>
<td>Estradiol treated</td>
<td>2030</td>
<td>0</td>
</tr>
<tr>
<td>Human serum standard*</td>
<td>362</td>
<td>65</td>
</tr>
<tr>
<td>Untreated lysate:serum (1:1)</td>
<td>567</td>
<td>38</td>
</tr>
<tr>
<td>Estradiol-treated lysate:serum (1:1)</td>
<td>1395</td>
<td>34</td>
</tr>
</tbody>
</table>

* Caltrol II, shown in our laboratory by electrophoresis to have isozymes 1, 2, 3, 4, and 5 in the percentages of 17, 22, 19, 10, and 32, respectively.

**Relative heat inactivation study of LDH activity in MCF-7 cell lysates, a human serum standard, and combinations**

**Chart 1. Characteristics of the LDH assay.** The change in absorbance (A240) due to the reduction of NAD+ was monitored at 340 nm. The reaction mixture contained 0.07 M L-lactate, 3.5 mM NAD+, and 0.05 M glycine buffer, pH 8.8. The time courses (A) began 30 sec after addition of 50 μl of sample to 3 ml of reaction mixture. Identical conditions were used to assay the effect of sample volume (B) on the LDH assay. , values obtained with lysates of MCF-7 cells grown on experimental medium as described in the text; O, data from a human serum standard (Caltrol II).
LDH, Estrogen, and Human Breast Cancer Cells

Chart 4. Dose response of the LDH activity in MCF-7 cells to estrogen. Cells were grown to confluence and then were exposed to 17β-estradiol at the indicated concentrations for an additional 5 days. •, mean of measured values for duplicate flasks. Growth conditions and the enzyme assay are described in "Materials and Methods."

thus characterized as a prerequisite to determining its potential usefulness as a marker protein of estrogen action.

We find (a) that MCF-7 cells have very high levels of LDH activity, (b) that only the fifth isoenzyme is present, and (c) that estradiol stimulates LDH levels. The significance of the high levels and the form of LDH in MCF-7 cells is uncertain. These levels are higher than those found in serum, even in disease states, but are in the range reported for normal or malignant breast tissues (6). Total LDH in infiltrating ductal carcinoma was reported to be 2-fold that of normal breast, fibrocystic disease, or fibroadenoma (6). Whether elevated levels are principally due to increased synthetic rates or to decreased intracellular metabolism or slowed excretion rates is unknown.

Also potentially of interest in human breast cancer is the demonstration that only the fifth isoenzyme of LDH is present in MCF-7 cells. Several investigators have reported an elevation in the proportion of LDH-5 in human breast neoplasia compared to that in normal breast tissue (4, 6, 16), and estradiol increases the rate of LDH-5 synthesis in uteri of immature rabbits and rats (5).

The search in MCF-7 cells for specific and useful markers of estrogen action that lie distal to the binding of estrogen to its receptor molecules and subsequent gene activation has met with some success. Progesterone receptor has been shown to be such a product (7, 8). LDH itself has the potential to control metabolic functions crucial to growth and may thus prove to be quite useful.

REFERENCES


R. E. Burke et al.


Lactate Dehydrogenase in Estrogen-responsive Human Breast Cancer Cells

Robert E. Burke, Steven C. Harris and William L. McGuire


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/38/9/2773

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.